Wnt5a, a New Diabetic Corneal Marker Related to Wound Healing

Wnt5a,一种与伤口愈合相关的新糖尿病角膜标记物

基本信息

  • 批准号:
    10682429
  • 负责人:
  • 金额:
    $ 41.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

Diabetes is the most widespread blinding disease in working-age adults. Up to 70% of diabetic patients suffer from corneal problems including neuropathy and epithelial keratopathy (impaired wound healing, ulcers, recurrent erosions) that impair vision and cause pain and discomfort. Diabetic keratopathy is underdiagnosed, and therapy remains symptomatic. We previously identified markers altered in human diabetic corneas and normalized their levels in human corneal organ cultures by gene and nano therapy, which also restored normal stem cell phenotype and corneal wound healing. Epigenetic changes may contribute to diabetic complications. Therefore, we examined epigenetic DNA methylation in human diabetic corneas and found a set of genes abnormally methylated vs. normal corneas. WNT5A gene, a noncanonical member of Wnt regulators of cell motility, proliferation and differentiation, was hypermethylated in diabetic corneas. Its expression was reduced in diabetic corneas and stem cell-enriched epithelial cultures. Wnt5a addition accelerated wound healing in diabetic (but not in normal cells), with stem cell marker expression increase. Inhibition of diabetes-increased miRNA-203a targeting WNT5A increased Wnt5a and wound healing in diabetic cells. miRNA-203a inhibitor and WNT5A siRNA reduced wound healing in normal cells. We will identify mechanisms of action of new diabetic marker Wnt5a, its effects on diabetic corneal cell populations, and normalize its levels in diabetic corneal cells. We hypothesize that normalization of diabetes-impaired stem cell phenotype and epithelial wound healing may be achieved by restoring normal expression of noncanonical Wnt5a by blocking its inhibiting microRNA with a novel nanoconjugate and using demethylating agents. Specific Aim 1. To identify Wnt5a receptor(s) mediating its effects on diabetic epithelial cells and corneas. Wnt5a receptors in diabetic limbal cells and corneas will be identified by imaging and functionally, by siRNAs, focusing first on ROR2. This will allow modulating their expression and signaling in diabetic cells to boost Wnt5a effects. Specific Aim 2. To examine Wnt5a effects on epithelial wound healing and limbal cell populations in human organ-cultured diabetic corneas. In these corneas, we will confirm normalizing Wnt5a effects using wound healing and stem cell marker expression. Changes in limbal epithelial differentiated and stem cell populations upon Wnt5a (or inhibitors) treatment will be examined by single cell RNA-seq vs. control normal cells. Specific Aim 3. To test the efficacy of therapies aimed at increasing Wnt5a expression using cultured diabetic cells and organ-cultured corneas. Diabetic limbal epithelial cells and corneas will be treated with nanoconjugate with miR-203a specific antagonist and/or with demethylating 5-Aza-2′-deoxycytidine (Decitabine) or Zebularine. Our aims fit well the priorities set in the NEI Vision Research: Needs, Gaps, and Opportunities. These priorities include (1) improving the transplantation of cultured corneal epithelial cells, (2) understanding of the epigenetic regulation of wound healing, and (3) developing methods to enhance the wound healing process.
糖尿病是工作年龄成年人中最普遍的致盲疾病。高达70%的糖尿病患者 包括神经病变和上皮角膜病变(伤口愈合受损,溃疡, 复发性糜烂),损害视力并引起疼痛和不适。糖尿病性角膜病变诊断不足, 治疗仍然是对症治疗我们先前确定了人类糖尿病角膜中改变的标记物, 通过基因和纳米治疗使它们在人类角膜器官培养物中的水平正常化,这也恢复了正常的 干细胞表型与角膜创伤愈合表观遗传变化可能导致糖尿病并发症。 因此,我们检测了人类糖尿病角膜中的表观遗传DNA甲基化,发现了一组基因, 异常甲基化与正常角膜。WNT 5A基因是细胞Wnt调节子中的一个非经典成员 运动、增殖和分化,在糖尿病角膜中是高甲基化的。其表达减少, 糖尿病角膜和富含干细胞的上皮培养物。Wnt 5a的加入加速了创伤愈合, 糖尿病(但不是在正常细胞中),干细胞标志物表达增加。抑制糖尿病-增加 靶向WNT 5A的miRNA-203 a增加了糖尿病细胞中的Wnt 5a和伤口愈合。miRNA-203 a抑制剂和 WNT 5A siRNA减少正常细胞中的伤口愈合。我们将确定新的糖尿病的作用机制, 标记物Wnt 5a,其对糖尿病角膜细胞群的影响,并使其在糖尿病角膜细胞中的水平正常化。 我们假设糖尿病受损的干细胞表型和上皮损伤的正常化 通过阻断非典型Wnt 5a的表达,恢复其正常表达, 用新的纳米缀合物和使用脱甲基化剂抑制微小RNA。 具体目标1。鉴定介导其对糖尿病上皮细胞和角膜作用的Wnt 5a受体。Wnt5a 糖尿病角膜缘细胞和角膜中的受体将通过成像和功能,通过siRNA,聚焦 首先是ROR 2。这将允许调节它们在糖尿病细胞中的表达和信号传导,以增强Wnt 5a的作用。 具体目标2。研究Wnt 5a对人类上皮伤口愈合和角膜缘细胞群的影响 器官培养的糖尿病角膜在这些角膜中,我们将使用伤口愈合来证实正常化Wnt 5a效应。 愈合和干细胞标志物表达。角膜缘上皮分化和干细胞群的变化 在Wnt 5a(或抑制剂)处理后,将通过单细胞RNA-seq相对于对照正常细胞来检查。 具体目标3。为了测试旨在使用培养的糖尿病细胞增加Wnt 5a表达的疗法的功效, 细胞和器官培养的角膜。糖尿病角膜缘上皮细胞和角膜将用纳米缀合物治疗 与miR-203 a特异性拮抗剂和/或与去甲基化5-氮杂-2 ′-脱氧胞苷(地西他滨)或Zebularine。 我们的目标非常符合NEI愿景研究中设定的优先事项:需求,差距和机会。这些 优先事项包括(1)改进培养的角膜上皮细胞的移植,(2)了解 创伤愈合的表观遗传调节,和(3)开发增强创伤愈合过程的方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander V Ljubimov其他文献

Alexander V Ljubimov的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander V Ljubimov', 18)}}的其他基金

Targeting tumor microenvironment by nanoimmunodrugs for glioma treatment
纳米免疫药物靶向肿瘤微环境治疗神经胶质瘤
  • 批准号:
    10743942
  • 财政年份:
    2023
  • 资助金额:
    $ 41.75万
  • 项目类别:
Wnt5a, a New Diabetic Corneal Marker Related to Wound Healing
Wnt5a,一种与伤口愈合相关的新糖尿病角膜标记物
  • 批准号:
    10468981
  • 财政年份:
    2020
  • 资助金额:
    $ 41.75万
  • 项目类别:
Wnt5a, a New Diabetic Corneal Marker Related to Wound Healing
Wnt5a,一种与伤口愈合相关的新糖尿病角膜标记物
  • 批准号:
    10254336
  • 财政年份:
    2020
  • 资助金额:
    $ 41.75万
  • 项目类别:
2020 Cornea and Ocular Surface Biology and Pathology GRC/GRS
2020年角膜和眼表面生物学与病理学GRC/GRS
  • 批准号:
    9913789
  • 财政年份:
    2019
  • 资助金额:
    $ 41.75万
  • 项目类别:
Transplantable limbal cells from induced pluripotent stem cells
来自诱导多能干细胞的可移植角膜缘细胞
  • 批准号:
    8659460
  • 财政年份:
    2013
  • 资助金额:
    $ 41.75万
  • 项目类别:
Transplantable limbal cells from induced pluripotent stem cells
来自诱导多能干细胞的可移植角膜缘细胞
  • 批准号:
    8849448
  • 财政年份:
    2013
  • 资助金额:
    $ 41.75万
  • 项目类别:
Transplantable limbal cells from induced pluripotent stem cells
来自诱导多能干细胞的可移植角膜缘细胞
  • 批准号:
    8503490
  • 财政年份:
    2013
  • 资助金额:
    $ 41.75万
  • 项目类别:
Mechanisms of Epithelial Alterations in Diabetic Cornea
糖尿病角膜上皮改变的机制
  • 批准号:
    8042795
  • 财政年份:
    2001
  • 资助金额:
    $ 41.75万
  • 项目类别:
Mechanisms of Epithelial Alterations in Diabetic Cornea
糖尿病角膜上皮改变的机制
  • 批准号:
    8827343
  • 财政年份:
    2001
  • 资助金额:
    $ 41.75万
  • 项目类别:
Mechanisms of Epithelial Alterations in Diabetic Cornea
糖尿病角膜上皮改变的机制
  • 批准号:
    7289238
  • 财政年份:
    2001
  • 资助金额:
    $ 41.75万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 41.75万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了